new drug under development

systematic review meta-analysis network meta-analysis

Select acute heart failure All type of patient       beta-blockershuman B-type natriuretic peptidelevosimendanrelaxineselective adenosine-1 receptor antagonistultrafiltration levosimendannesiritiderolofylline serelaxintonapofylline vs placebo or controlvs active treatment      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results NCT results	30-day deathAll cause deathCardiovascular deathheart failure death death or hospitalization amelioration of Dyspnea at 24 hAmelioration of Dyspnea at 6 h BNP under treatment Cardiovascular death or hospital admission for CHF CV death, MI hospitalization for HF Death from any cause or hospitalization for heart failurehospitalisation for cardiovascular causes hospitalisation for heart failure
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result
acute heart failure
levosimendan
REVIVE II, 2013      NCT	levosimendan	placebo			Low risk of bias	-
REVIVE-I, 2003	levosimendan	placebo			Exploratory	remark
RUSSLAN, 2002	levosimendan	placebo			Low risk of bias	remark
SURVIVE, 2007    NCT	levosimendan	dobutamine			Low risk of bias	negative
CASINO	levosimendan	dobutamine			Low risk of bias	remark
LIDO, 2002	levosimendan	dobutamine			Low risk of bias	remark
nesiritide
NSGET (comparative trial), 2000	nesiritide	control			Low risk of bias	remark
NSGET (efficacy trial), 2000	nesiritide	placebo			Low risk of bias	negative
PROACTION, 2003	nesiritide	placebo			Low risk of bias	negative
BNP-CARDS, 2007          NCT	nesiritide	placebo			Low risk of bias	remark
FUSION 2, 2008        NCT	nesiritide	placebo			Low risk of bias	remark
ASCEND-HF, 2011        NCT	nesiritide	placebo			Low risk of bias	negative
VMAC (intravenous neseritide), 2002      NCT	nesiritide	placebo			Low risk of bias	remark
PRECEDENT, 2002      NCT	nesiritide	dobutamine			Exploratory	remark
VMAC (24h), 2002      NCT	nesiritide	nitroglycerin			Risk of bias	negative
FUSION 1, 2004    NCT	nesiritide	standard care			Low risk of bias	remark
rolofylline
PROTECT, 2010    NCT	rolofylline	placebo			Low risk of bias	negative
serelaxin
Pre-RELAX-AHF, 2009      NCT	serelaxin	placebo			Low risk of bias	-
RELAX-AHF, 2013      NCT	serelaxin	placebo				-